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Premature degradation of CFTRF508 causes cystic fibrosis (CF). CFTRF508 folding defects are conditional and folding
correctors are being developed as CF therapeutics. How the cellular environment impacts CFTRF508 folding efficiency
and the identity of CFTRF508’s correctable folding defects is unclear. We report that inactivation of the RMA1 or CHIP
ubiquitin ligase permits a pool of CFTRF508 to escape the endoplasmic reticulum. Combined RMA1 or CHIP inacti-
vation and Corr-4a treatment enhanced CFTRF508 folding to 3–7-fold greater levels than those elicited by Corr-4a. Some,
but not all, folding defects in CFTRF508 are correctable. CHIP and RMA1 recognize different regions of CFTR and a
large pool of nascent CFTRF508 is ubiquitinated by RMA1 before Corr-4a action. RMA1 recognizes defects in
CFTRF508 related to misassembly of a complex that contains MSD1, NBD1, and the R-domain. Corr-4a acts on
CFTRF508 after MSD2 synthesis and was ineffective at rescue of F508 dependent folding defects in amino-terminal
regions. In contrast, misfolding caused by the rare CF-causing mutation V232D in MSD1 was highly correctable by
Corr-4a. Overall, correction of folding defects recognized by RMA1 and/or global modulation of ER quality control has
the potential to increase CFTRF508 folding and provide a therapeutic approach for CF.
INTRODUCTION
Cystic fibrosis (CF) is a lethal inherited disorder that is
caused by mutations in the gene coding for the CF trans-
membrane conductance regulator (CFTR; Riordan et al.,
1989). The CFTR protein is a cAMP-regulated chloride chan-
nel that is localized to the apical surface of epithelial cells (Li
et al., 1988; Anderson et al., 1991) where it functions to
regulate water and salt homeostasis. Inheritance of the
CFTRF508 gene, in which phenylalanine 508 is deleted
from the nucleotide binding domain 1 (NBD1), is the major
cause of CF. This prevalent mutation is found in 90% of
patients afflicted with CF (Bobadilla et al., 2002). Loss of
functional CFTR alters the hydration of airway epithelial
and gives rise to microbial infections, which can ultimately
lead to lung failure and death (Rowe et al., 2005).
CFTR, an ATP-binding cassette (ABC) transporter super-
family member (Hyde et al., 1990), is a 1480-residue polyto-
pic membrane glycoprotein that is predicted to contain two
membrane-spanning domains (MSD), two nucleotide-bind-
ing domains (NBD), and a regulatory domain (R; Riordan et
al., 1989). The folding of CFTR into a functional chloride
channel is complex because it requires the coordinated fold-
ing and assembly of its membrane and cytoplasmic domains
(Du et al., 2005; Cui et al., 2007). Consequently, CFTR folding
is a relatively inefficient process with 70% of the wild type
and 99% of the F508 mutant being partitioned from a
folding to a degradation pathway (Ward and Kopito, 1994).
However, although early stage biogenic intermediates of
CFTR and CFTRF508 appear to have similar conformations
(Zhang et al., 1998), the folding of CFTRF508 becomes
arrested at a poorly defined step. Interestingly, deletion of
the F508 residue causes subtle structural changes in the
NBD1 domain as well as defective interaction between
NBD1 and other subdomains of CFTR (Du et al., 2005; Thi-
bodeau et al., 2005).
The assembly of native CFTR into a conformation that can
bypass the endoplasmic reticulum quality control (ERQC) sys-
tem occurs in both co- and posttranslational steps (Kleizen et
al., 2005) that are proposed to involve critical interactions
between the NBD and MSD interfaces (Dawson and Locher,
2006; Mendoza and Thomas, 2007; Mornon et al., 2008; Se-
rohijos et al., 2008). Recent molecular modeling analysis and
cross-linking studies suggest that NBD1 contacts the cyto-
plasmic loop (CL) 1 of MSD1 and CL3 and 4 of MSD2,
whereas NBD2 interacts with CL1 and 2 of MSD1 and CL3
of MSD2 (He et al., 2008; Mornon et al., 2008; Serohijos et al.,
2008). The F508 residue, located in a surface exposed loop
within the NBD1 domain (Lewis et al., 2004; Thibodeau et al.,
2005), is proposed to help orient NBD1 and stabilize the
overall CFTR structure by making contacts with solvent
exposed surfaces of CL4 of MSD2 (Mornon et al., 2008;
Serohijos et al., 2008). The F508 side chain also appears to be
required for proper assembly of a folding intermediate that
contains MSD1, NBD1, and the R-domain whose formation
may be critical for completion of CFTR folding (Rosser et al.,
2008). This supposition is supported by the observation that
loss of F508 leads MSD2 to accumulate in an altered confor-
mation and hinders posttranslational folding of NBD2 (Du et
al., 2005; Du and Lukacs, 2009). Because deletion of F508
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from CFTR alters the assembly of more than one CFTR
region, the folding defects that lead to its selection for pre-
mature degradation and the onset of CF remain unclear.
The folding progression of CFTR is monitored by at least
two distinct ERQC complexes that are located in the ER
membrane and cytosol. One ubiquitin ligase complex that
recognizes CFTR is composed of the ERQC factor Derlin-1,
the E2 Ubc6e, and the E3 ligase RMA1, which form an ER
membrane–associated complex (Younger et al., 2006). In ad-
dition, Hsc70, the E2 UbcH5a, and the E3 ligase CHIP also
act in the cytosol to monitor the conformation of CFTR
(Meacham et al., 1999, 2001; Younger et al., 2004). CFTR
translation intermediates exhibit differential sensitivity to
changes in RMA1 or CHIP activity, leading to the interpre-
tation that these ubiquitin ligase complexes selectively rec-
ognize different regions of CFTR (Younger et al., 2006). The
membrane-associated RMA1 complex appears to recognize
folding defects in CFTR that may involve misassembly of
MSD2 into a complex with the amino-terminal regions of
CFTR. In contrast, the cytosolic CHIP complex appears to
sense folding defects that are related to misassembly of the
NBD2. CFTRF508 is more sensitive to changes in RMA1
activity than CFTR, which suggests that RMA1 plays a crit-
ical role in CFTRF508’s premature degradation (Younger et
al., 2004).
Misfolded forms of CFTR that are recognized by the
ERQC machinery and are polyubiquitinated can subse-
quently be acted upon by gp78. Gp78, an E3 ligase that
contains a polyubiquitin chain–binding CUE domain, inter-
acts with RMA1 and acts to maintain ubiquitin chain length
(Morito et al., 2008) before CFTR’s retrotranslocation by p97
(Dalal et al., 2004) from the ER membrane and degradation
by cytosolic proteasomes (Cheng et al., 1990; Jensen et al.,
1995; Ward et al., 1995; Meacham et al., 2001). This pathway
for quality control of CFTR is likely to contain additional
components. In addition, how modulation of endogenous
ERQC factors impacts the folding efficiency of CFTR and
CFTRF508 is not clear. Furthermore, the nature of the
correctable defects that limit folding of CFTRF508 is un-
known.
What we know is that a portion of the folding defects
caused by deletion of F508 are conditional and small pools of
misfolded CFTRF508 intermediates can be rescued by low
temperature incubations or by chemical chaperones in cell
culture systems (Denning et al., 1992; Brown et al., 1996; Sato
et al., 1996). A number of high-throughput screens have been
conducted and an array of small-molecule chemical correc-
tors have been found to weakly enhance the folding of
CFTRF508 (Pedemonte et al., 2005; Van Goor et al., 2006).
Corr-4a, a bisaminomethylbithiazole derivative, is currently
the most effective chemical corrector available to the re-
search community (Figure 1A). Treatment with Corr-4a in-
creases the cell surface expression of a small pool of
CFTRF508 in human airway epithelia, making this com-
pound a potentially attractive candidate for CF treatment
(Pedemonte et al., 2005). In addition, Corr-4a not only
improves trafficking of CFTRF508 to the plasma mem-
brane, but it also appears to enhance the cell surface stability
of the rescued mutant protein (Varga et al., 2008). The mech-
anism by which Corr-4a modulates the folding of
CFTRF508 is unknown. Recent literature suggests that
Corr-4a may bind directly to CFTR based on its ability to
block specific cross-links between membrane segments of
CFTR (Wang et al., 2007); however, direct evidence of a
drug-binding pocket on CFTR is lacking. Thus, it is currently
unclear if Corr-4a has a direct or indirect affect on the folding
of CFTRF508.
In this study we sought to define the extent to which
activity of the ERQC machinery limits CFTRF508 folding
and to identify which folding defects in CFTRF508 are
correctable. Toward this goal, we observed an increase in
both the folding of CFTRF508 and the activity of Corr-4a
when endogenous levels of the E3 ligases RMA1 or CHIP
were depleted by small interfering RNA (siRNA). We also
demonstrated that deletion of F508 causes folding defects
that are both correctable and noncorrectable by Corr-4a. The
noncorrectable defect in CFTRF508 occurs early in its bio-
genesis and involves misfolding of N-terminal regions that
contain MSD1, NBD1, and the R-domain. The correctable
folding defect occurs after synthesis of MSD2. Corr-4a acts in
part via stabilization of the MSD2, which may enhance
critical contacts between MSD2 and other subdomains of
CFTR, such as MSD1 or NBD1. Surprisingly, we also dis-
covered that Corr-4a can strongly correct the folding defects
of less common CF disease-causing point mutations. Collec-
tively, our data indicate that modulation of ERQC activity can
increase the accumulation of foldable pools of CFTRF508 and
enhance Corr-4a action. Some of the misfolded CFTR interme-
diate species can be brought back on pathway, whereas others
appear more difficult to fix.
MATERIALS AND METHODS
Plasmids, Antibodies, and Reagents
CFTR expression plasmids pcDNA3.1()-CFTR and pcDNA3.1()-
CFTRF508 have been described elsewhere (Meacham et al., 2001). CFTR
constructs representing CF disease-causing point mutants or biogenic inter-
mediates were made using the QuikChange protocol (Stratagene, La Jolla,
CA). Antibodies used in this study were as follows: -CFTR MM13– 4
(N-terminal tail epitope) and -CFTR M3A7 (NBD2 epitope) were from
Millipore (Billerica, MA); -RMA1 (sc81716) was from Santa Cruz Biotech-
nology (Santa Cruz, CA); and -tubulin was purchased from Sigma (St. Louis,
MO). The polyclonal -CHIP antibody used in our studies was generated
against full-length recombinant CHIP protein. Polyclonal -CFTR, generated
against a glutathione S-transferase (GST) fusion protein that contained
CFTR residues 1–79, was a generous gift from Dr. Kevin Kirk (University
of Alabama Birmingham). Corr-4a was provided by the Cystic Fibrosis Foun-
dation and Dr. Robert Bridges (Rosalind Franklin University). An initial
titration of Corr-4a, prepared in DMSO, indicated that a final concentration of
5 M was sufficient to observe maximal maturation of CFTRF508.
Cell Culture and Transfection
Human embryonic kidney (HEK) 293 cells from Stratagene were maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and anti-
biotics (100 U/ml penicillin and 100 g/ml streptomycin; Invitrogen) at 37°C
in an atmosphere of 5% CO2. Cell transfections were performed using Effect-
ene reagent (Qiagen, Valencia, CA) or Lipofectamine 2000 (Invitrogen) where
indicated. The empty pcDNA3.1() vector was used to ensure equal micro-
gram quantities of DNA were used in all transfection reactions.
Analysis of CFTR Biogenesis
CFTR Steady-State Levels. Steady-state levels of CFTR and its mutants were
determined by Western blot analysis. HEK293 cells were transiently trans-
fected with the indicated plasmids. The transfected cells were allowed to
recover for 18 h before addition of DMEM (10% FBS and antibiotics)
supplemented with Corr-4a (5 M final concentration) or DMSO. The cells
were incubated with the chemicals for 24 h before isolating the cells for
Western blot analysis. The harvested cells were diluted with 2 SDS sample
buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 0.05% bromophenol blue, and 20%
glycerol), sonicated, and heated at 37°C before resolving the proteins on
SDS-PAGE gels. The proteins were transferred to nitrocellulose membranes,
and the membranes were probed with the designated antibodies. -Tubulin
was used to indicate loading controls.
CFTR Processing Efficiency. CFTR processing efficiency was measured by
pulse-chase analysis. Transiently transfected HEK293 cells were allowed to
recover for 18 h. The cells were then incubated with DMEM (10% FBS and
antibiotics) supplemented with Corr-4a or DMSO for 2 h. Next, cells were
starved in methionine-free MEM (Sigma) for 20 min, pulse-labeled for 20 min
with [35S]methionine (100 Ci/6 well; 1200 Ci/mmol; MP Biomedicals, Ir-
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vine, CA), and then chased for the indicated amount of time. Corr-4a or
DMSO was also included in the media during these steps of the pulse-chase
reaction. Cells were then lysed in PBS buffer supplemented with 1% Triton
(PBS-T, 1%), 1 mM PMSF, and Complete protease inhibitor cocktail (Roche,
Indianapolis, IN). Soluble lysates were obtained by centrifugation at 20,000
rpm for 10 min in a Beckman Allegra 64R centrifuge (Fullerton, CA). Equal
microgram quantities of cell lysate were subjected to immunoprecipitation by
incubation with a polyclonal -CFTR antibody directed against the N-termi-
nus followed by addition of a 50% protein G bead slurry. The beads were
washed with PBS-T (1%) supplemented with 0.2% SDS, the bound CFTR was
eluted with 2 SDS sample buffer, and the samples were heated at 55°C for
10 min. The samples were analyzed by SDS-PAGE and visualized by auto-
radiography.
RNA Interference Analysis
HEK293 cells were transfected at a final total concentration of 100 nM with
oligonucleotides (oligos) directed at either RMA1 (sequence 1, GCGCGAC-
CUUCGAAUGUAA; sequence 2, CGGCAAGAGUGUCCAGUAU), CHIP
(sequence 1, GGAGCAGGGCAAUCGUCUG; sequence 2, CCAAGCACGA-
CAAGUACAU), or a nonspecific control (Dharmacon, Lafayette, CO) by
using the transfection reagent Lipofectamine 2000 (Invitrogen). Forty-eight
hours later 1 g of CFTR or CFTRF508 was introduced into the cells using
Effectene (Qiagen) as the transfection reagent. For steady-state analysis
Corr-4a or DMSO was added to the cells 4 h after the second transfection, and
the cells were harvested 24 h later. Then 2 SDS sample buffer was added to
cell pellets, and after sonication the samples were normalized to contain the
same total amount of protein. The reactions were resolved on SDS-PAGE gels,
transferred to nitrocellulose membranes, and the membranes were probed
with the indicated antibodies. -Tubulin was used to indicate loading con-
trols. For pulse-chase analysis the cells were allowed to recover for 18 h after
the second transfection. The cells were then incubated with DMEM (10% FBS
and antibiotics) supplemented with Corr-4a or DMSO for 2 h. The pulse-chase
procedure utilized is similar to that described above within the CFTR pro-
cessing efficiency subsection.
RESULTS
Inactivation of ERQC Checkpoints Permits CFTRF508
Folding and Enhances Corr-4a Activity
The extent that activity of the ERQC machinery determines
the fate of nascent forms of CFTR and CFTRF508 is unclear.
In addition, whether activity of the ERQC machinery im-
pacts the effectiveness of drugs developed to correct mis-
folding of CFTRF508 is unknown. Thus, we sought to gain
insight into the mechanism for premature degradation of
CFTR and CFTRF508 through inactivating the known
ERQC checkpoints and determining the effect this had on
CFTR and CFTRF508 folding in the presence or absence of
Corr-4a. This was accomplished by evaluating the accumu-
lation of the folded C-form of CFTR and CFTRF508 when
endogenous levels of either the E3 ligase RMA1 or the E3
ligase CHIP was depleted by siRNA in the absence and
presence of Corr-4a (Figure 1). Knockdown of endogenous
RMA1 or CHIP levels resulted in a respective 3.4- and 2.3-
fold increase in the accumulation of the C-form of CFTR,
which was also accompanied by an increase in B-form levels
(Figure 1B). As shown in Figure 1C, the endogenous levels
of either RMA1 or CHIP are reduced to greater than 90%
using RNA interference (RNAi). Corr-4a treatment alone is
able to elevate the levels of the folded, maturely glycosy-
lated, C-form of CFTR 3.9-fold, whereas the levels of non-
native, ER localized and immaturely glycosylated B-form
were increased by 1.7-fold (Figure 1B). The combined knock-
down of either RMA1 or CHIP and treatment with Corr-4a
further enhanced accumulation of CFTR to levels around
fivefold greater than the DMSO-treated control siRNA reac-
tion. Thus, inactivation of either the RMA1 or CHIP E3
quality control checkpoints permits a larger pool of folded
CFTR to accumulate and greatly influences the potency of
Corr-4a action.
The positive effects of the combined knockdown of ERQC
factors and Corr-4a treatment on CFTRF508 folding were
more dramatic than those observed with CFTR. Knockdown
of RMA1 was nearly as effective as Corr-4a treatment at
permitting CFTRF508 to accumulate in its folded C-form,
whereas knockdown of CHIP was about half as effective
(Figure 1B). Amazingly, the knockdown of endogenous
RMA1, in addition to Corr-4a treatment, led to a 13-fold in-
crease in the accumulation of the C-form of CFTRF508 and
only a 1.8-fold increase in levels of its B-form. Furthermore, the
combination of CHIP knockdown and Corr-4a treatment in-
creased the accumulation of the C-form of CFTRF508 eight-
fold while its B-form levels were increased by 1.5-fold. Thus,
inactivation of either RMA1 or CHIP permits a foldable pool
of CFTRF508 to accumulate and the folding of this pool of
CFTRF508 is greatly augmented by Corr-4a.
To determine whether modification of the cellular folding
environment through inactivation of ERQC factors in-
creased the folding efficiency of CFTR, we conducted a series
Figure 1. Knockdown of ER quality control checkpoints enhance
CFTRF508 folding and Corr-4a activity. (A) Chemical structure of
small molecule corrector Corr-4a. (B) Transfections with siRNA
oligos and CFTR or CFTRF508 were performed as described in
Materials and Methods. The siRNA samples were treated with DMSO
or Corr-4a as indicated. Twenty-four hours later the samples were
lysed in 2 SDS sample buffer and normalized to total amount of
protein, and Western blot analysis was used to determine the
steady-state levels of either CFTR or CFTRF508. Bands B and C
represent the immature and maturely glycosylated forms of CFTR,
respectively. Tubulin blots were used as loading controls. The B-
and C-band levels for each reaction were quantified by densitome-
try and were normalized to the DMSO-treated reaction which con-
tained the siRNA control duplex (cont-siRNA). Results shown are
representative of one experiment, but trends were identical when
the experiment was repeated three individual times. (C) A mono-
clonal RMA1 antibody and a polyclonal CHIP antibody were used
to monitor the impact of RNAi addition on endogenous RMA1 and
CHIP levels, respectively.
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of pulse-chase experiments under the same experimental
conditions as described in Figure 1. In the presence of con-
trol siRNA, 20% of the immature B-form of CFTR was con-
verted to its folded C-form with DMSO treatment, whereas
the addition of Corr-4a increased the efficiency of this pro-
cess around 2.5-fold (Figure 2A). Interestingly, knockdown
of RMA1, but not CHIP, led to a twofold increase in CFTR
folding efficiency. When RMA1 siRNA cells were treated
with Corr-4a, 83% of the total quantity of the B-form of
CFTR could be converted to its C-form. Although knock-
down of CHIP did not detectably increase CFTR folding
efficiency, the combination of CHIP siRNA and Corr-4a
treatment increased CFTR maturation from 20 to 65%. Thus,
inactivation of ERQC factors has the potential to increase the
folding efficiency of nascent CFTR and appears to permit the
accumulation of larger pools of foldable molecules that can
be acted upon by chemical corrector Corr-4a in the ER.
Increased accumulation of the C-form of CFTRF508 was
observed when RMA1 or CHIP levels were knocked down
by siRNA and also upon Corr-4a treatment (Figure 1B). Yet,
increased folding of CFTRF508 was not readily observed in
pulse-chase experiments (Figure 2B). Nevertheless, as com-
pared with the appropriate control (Figure 2B, top panel)
2–4-fold more of the B-form of CFTRF508 was observed at
the end of pulse-chase time courses when either RMA1 or
CHIP levels were decreased and/or Corr-4a was present.
Thus, the half-life of CFTRF508 is increased upon inactiva-
tion of ERQC complexes and/or Corr-4a treatment, but the
quantity that can fold to the native state is too small to detect
after a 20-min pulse-labeling period and subsequent chase.
Nevertheless, inactivation of ERQC factors can spare a pool
of nascent CFTRF508 from degradation and permit its
proper folding and this pool is detected via western blot as
a maturely glycosylated species after a 24-h time period.
These data indicate that large portions of foldable nascent
CFTR and CFTRF508 are selected by the ERQC machinery
for degradation before reaching the native state. Therefore,
inactivation of the ERQC machinery can spare both nascent
CFTR and CFTRF508 from degradation and permits accu-
mulation of a larger pool of protein that can be brought onto
the folding pathway in the ER by Corr-4a.
Corr-4a Appears to Act on CFTR and CFTRF508
Biogenic Intermediates in the ER after Synthesis of MSD2
Data presented thus far indicate that the folding pathway
of CFTR can be altered by Corr-4a. Yet, large pools of
CFTRF508 in Corr-4a treated cells are still recognized by
ERQC machinery and irreversibly leave the folding path-
way. To understand why Corr-4a action can be enhanced by
inactivation of ERQC machinery, we sought to define the
correctable defective folding steps in CFTR and CFTRF508.
To accomplish this we determined the effect of Corr-4a on the
steady-state levels of CFTR and CFTRF508 fragments that
resemble different length biogenic intermediates (Younger et
al., 2006; Cui et al., 2007; Rosser et al., 2008; Figure 3).
HEK293 cells, transiently transfected with the indicated
CFTR biogenic fragments (Figure 3A), were incubated with
Corr-4a or DMSO and the steady-state levels of CFTR were
assessed (Figure 3B). CFTR 370X, which represents MSD1 of
CFTR, was unaffected by Corr-4a treatment. The MSD1-
NBD1 fragment CFTR 653X and CFTR 837X, which is trun-
cated after the R-domain, were also unaffected by Corr-4a.
Deletion of F508 causes a modest decrease in accumulation
of CFTR 653X and has a more dramatic effect on CFTR 837X
(Figure 3B; Rosser et al., 2008). However, Corr-4a did not
enhance the accumulation of the F508 deleted forms of either
CFTR 653X or CFTR 837X. Yet, we know that accumulation
Figure 2. Modulation of the cellular folding environment by
siRNA and Corr-4a affects the folding efficiency of CFTR and sta-
bility of CFTRF508. Transfections with siRNA oligos and CFTR (A)
or CFTRF508 (B) were performed as described in Materials and
Methods. The siRNA reactions were incubated with DMSO or
Corr-4a for 2 h before being pulse-labeled with [35S]methionine and
chased for the indicated time periods in the presence of chemical
treatment. Cell lysates were normalized to total amount of protein,
immunoprecipitated with a polyclonal CFTR N-terminal antibody,
and visualized by SDS-PAGE analysis and autoradiography. Aster-
isk denotes a background band. Results were quantified by densi-
tometry and normalized relative to the amount of B-band at t  0
min for each condition. Similar results were observed upon three
repeats of the pulse-chase experiment.
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of CFTR 837XF508 is dramatically enhanced by siRNA
knockdown of RMA1 (Rosser et al., 2008).
It is not until after synthesis of MSD2, shown here with the
CFTR 1172X biogenic intermediate, that we observed a sig-
nificant affect of Corr-4a. The CFTR 1172X fragment is able
to fold into a conformation that can escape the ERQC sys-
tem, become maturely glycosylated and traffic to the plasma
membrane (Cui et al., 2007). We observed an increase in the
accumulation of both the B- and C-forms of CFTR 1172X in
the presence of Corr-4a (Figure 3B). Similar to the full-length
CFTRF508 mutant, deletion of F508 inhibits formation of
the maturely glycosylated C-form of CFTR 1172X (Cui et al.,
2007). Yet, in contrast to what was observed with shorter
fragments, Corr-4a increased the accumulation of the B-form
of CFTR 1172XF508 (Figure 3B). However, Corr-4a was
ineffective at promoting the folding of CFTR 1172XF508.
Similar effects of Corr-4a on the different length CFTR
fragments were also observed in pulse-chase studies (Figure
3C). First, we found that the addition of Corr-4a does not
increase the biosynthesis of the various length 35S-labeled
CFTR fragments (compare t  0 for DMSO controls vs.
Corr-4a reactions for each CFTR fragment). Second, it was
apparent that deletion of F508 impacts the amount of 35S-
labeled starting product (t  0) and the stability of CFTR
837X and CFTR 1172X, and to a lesser extent CFTR 653X.
However, Corr-4a did not increase the shortened half-life of
CFTR 653XF508 or CFTR 837XF508. Yet, Corr-4a did in-
crease the folding efficiency of CFTR 1172X around 2.5-fold
and also increased the half-life of CFTR 1172XF508.
The extent that deletion of F508 can differentially affect the
levels of N-terminal fragments of CFTR are intriguing and
have previously been documented (Rosser et al., 2008). De-
letion of F508 has only a modest affect on the stability of the
MSD1-NBD1 fragment CFTR 653X, but the presence of the
R-domain results in a much more pronounced defect. It
appears that deletion of F508 in CFTR 837X dramatically
disrupts the assembly of MSD1, NBD1, and the R-domain
into a stable complex. Consequently, a large population of
837XF508 is selected for proteasomal degradation by the E3
ligase RMA1 (Rosser et al., 2008). Thus, it is not surprising
that the accumulation and 35S-labeled starting product (t 
0) of CFTR 837XF508 is significantly lower than its wild-
type counterpart CFTR 837X.
Major conclusions that can be drawn from analyzing how
chemical corrector Corr-4a affects the biogenesis of CFTR
fragments that resemble biogenic intermediates are as fol-
lows: first, corrector-induced accumulation of CFTR frag-
ments was not observed until after synthesis of MSD2; sec-
ond, folding defects caused by deletion of F508 that occur
before synthesis of MSD2 do not appear to be corrected by
Corr-4a addition alone; and third, the corrector-induced
maturation of CFTRF508, but not CFTR 1172XF508, sug-
gests that NBD2 has an important role in the conformational
maturation of CFTRF508.
transfection the cells were pretreated for 2 h with the indicated
chemicals, labeled with [35S]methionine, and chased for the indi-
cated amounts of time in the presence of chemical treatment. The
isolated cells were lysed, soluble cell lysates were normalized to
contain the same total amount of protein, and CFTR was immuno-
precipitated with a polyclonal N-terminal CFTR antibody. The im-
munoprecipitates were visualized by SDS-PAGE analysis and au-
toradiography. Results were quantified by densitometry and
normalized to the amount of B-band at t  0 for each CFTR con-
struct and chemical treatment. For each CFTR fragment, the steady-
state (B) and pulse-chase (C) results are consistent and the observed
trends reproducible.
Figure 3. Corr-4a appears to act on CFTR and CFTRF508 bio-
genic intermediates after synthesis of MSD2. (A) A schematic de-
picting the amino acid position in CFTR where stop codons were
introduced to generate the CFTR biogenic intermediates utilized in
B and C. HEK293 cells were transiently transfected with 1 g of the
indicated CFTR constructs. (B) Corr-4a or DMSO was added to
the cells 18 h after transfection, and the cells were incubated with
the chemicals for 24 h. The samples were subjected to Western blot
analysis with an antibody that specifically recognizes the N-termi-
nus of CFTR to determine steady-state levels of the CFTR fragments.
Bands B and C represent the immature and maturely glycosylated
forms of CFTR, respectively. Tubulin blots were performed to indi-
cate loading controls. The B- and C-band levels for each reaction
were quantified by densitometry and were normalized to the
DMSO-treated control. (C) For the pulse-chase reactions, 18 h after
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Overall, these data suggest that the mechanism of action
of Corr-4a involves the stabilization of an interaction inter-
face between MSD2 and a more N-terminal domain of
CFTR, which is disrupted by deletion of F508. In fact cross-
linking data suggests that deletion of F508 disrupts interac-
tions between MSD2 and MSD1 (Chen et al., 2004) as well as
MSD2 and NBD1 (Serohijos et al., 2008). Furthermore, the
fact that we observe correction of CFTRF508, but not CFTR
1172XF508, suggests that NBD2 may play a role in further
stabilizing the interface formed after Corr-4a addition.
Folding Defects Caused by CF Disease-related Mutations
in Different CFTR Subdomains Exhibit Varied Degrees of
Correction
Data presented herein, and by others (Chen et al., 2004; Du et
al., 2005; Mornon et al., 2008; Rosser et al., 2008; Serohijos et
al., 2008) indicate that there are multiple folding defects in
the pathway for CFTRF508 folding, yet the present data
implies that not all defects are correctable. Thus, we asked to
what extent can disease related folding defects caused by
mutations in MSD1 (G85E, G91R, and V232D), MSD2
(M1137R), and NBD2 (N1303K) be corrected relative to those
caused by deletion of F508 in NBD1 (Figure 4A). The G85E,
G91R, M1137R, and N1303K mutations all hinder folding of the
nascent B-form of CFTR via a mechanism that involves inser-
tion of a charged amino acid into an inappropriate region
(Gregory et al., 1991; Xiong et al., 1997; Vankeerberghen et al.,
1998). The V232D mutation has been proposed to introduce an
abnormal hydrogen bond within the transmembrane (TM) re-
gion of MSD1, which impedes normal TM assembly (Therien et
al., 2001), but the affect of this mutation on CFTR biogenesis is
unknown.
The effect of Corr-4a on the NBD2 mutant N1303K was
similar to that observed with CFTRF508 in that a small
degree of correction was observed (Figure 4A). The levels of
the immature form of CFTR N1303K were slightly elevated
while accumulation of the mature form was enhanced upon
addition of Corr-4a. Surprisingly, we observed dramatic
differences in the ability of Corr-4a to increase the quantity
of the folded forms of four different MSD mutants (Figure
4A). The CFTR G85E and G91R point mutations are con-
tained within TM1, whereas the V232D mutation lies within
TM4 of CFTR’s MSD1 domain. The CFTR M1137R mutation
exists within TM12 of CFTR’s MSD2 domain. The addition
of Corr-4a slightly increased the steady-state levels of CFTR
G85E B-form, but Corr-4a–dependent folding of this mutant
was not detected. Furthermore, chemical treatment of CFTR
G91R or CFTR M1137R did not significantly affect the accu-
mulation of the immature B-form; however, the mature C-
forms of both CFTR G91R and CFTR M1137R were appar-
ent. Thus, Corr-4a is not specific for the F508 deletion and
can increase the folding of a small pool of some, but not all,
CFTR mutants.
Intriguingly, introduction of the V232D mutation gener-
ates an unstable CFTR biogenic mutant with decreased lev-
els of the immature B-form and no apparent maturation
product (Figure 4A). Yet, treatment with Corr-4a resulted in
a dramatic increase in accumulation of both the immature
and mature forms of CFTR V232D. However, folding defects
in CFTR V232D were not significantly rescued by low tem-
perature incubations (data not shown). Pulse-chase analysis
indicated that Corr-4a strongly increases the folding effi-
ciency of CFTR V232D, and does not simply increase the
synthesis of this point mutant (Figure 4B). The ability of
Corr-4a to dramatically enhance CFTR V232D folding sug-
gests that this mutant may have a single folding defect in
MSD assembly that is correctable by Corr-4a. In agreement
with this idea, Corr-4a is able to enhance the accumulation
of the V232D-containing MSD1 fragment, CFTR 370X V232D
(data not shown). In contrast, the multiple folding defects
caused by deletion of F508 do not appear to be as readily
repaired by Corr-4a.
Corr-4a Stabilizes the MSDs of CFTR
To define in greater detail the defective step(s) in the
CFTRF508 folding pathway that can be corrected by Corr-
4a, we studied assembly of wild-type and mutant forms of
Figure 4. Folding defects caused by CF disease-related mutations
in different CFTR subdomains exhibit varied degrees of correction.
(A) HEK293 cells were transiently transfected with 1 g of the
indicated CF disease-causing mutants. The transfected cells were
allowed to recover for 18 h before addition of Corr-4a or DMSO. The
cells were incubated with chemicals for 24 h before using Western
blot analysis to determine the steady-state levels of the mutant
CFTR proteins. The immature and maturely glycosylated forms of
CFTR are designated as B- and C-bands, respectively. Tubulin is
used as a loading control. The B- and C-band levels of each CFTR
point mutant were quantified by densitometry and were normal-
ized to the DMSO-treated samples for each mutant. The affect of
Corr-4a on the studied CF disease causing mutants was reproduc-
ible (n  3). (B) Corr-4a increases the biosynthetic maturation of
CFTR V232D. HEK293 cells transfected with CFTR V232D (1 g)
were preincubated with Corr-4a or DMSO for 2 h, labeled with
[35S]methionine, and chased for the indicated amounts of time in the
continuous presence of chemical treatment. The cells were lysed,
soluble cell lysates were normalized to contain the same total
amount of protein, and CFTR was immunoprecipitated with a poly-
clonal N-terminal CFTR antibody. The reactions were visualized by
SDS-PAGE analysis and autoradiography. Results were quantified
by densitometry and graphed.
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split CFTR fragments that individually contain the N- and
C-terminal subdomains (Figure 5A). As shown earlier in
Figure 3, Corr-4a treatment does not affect accumulation of
the stable N-terminal fragment CFTR 837X (Figure 5B).
However, the C-terminal fragment CFTR 837-1480 is unsta-
ble (Rosser et al., 2008), and steady-state levels of it are
increased by Corr-4a (Figure 5B). In addition, pulse-chase
analysis indicates that Corr-4a increases the half-life of CFTR
837-1480 (Figure 5C).
Coexpression of the two halves of CFTR increases the
accumulation of CFTR 837-1480, as well as, promotes the
formation of a maturely glycosylated form of CFTR 837-1480
(Rosser et al., 2008). Addition of Corr-4a to the coexpressed
CFTR halves significantly increased the levels of CFTR 837-
1480 and also enhanced interactions of the two halves of CFTR
such that more folded maturely glycosylated CFTR 837-1480
accumulates (Figure 5D). Thus, Corr-4a can stabilize mem-
brane inserted domains of CFTR and may thereby enhance the
association and folding of N- and C-terminal regions.
To further probe the nature of the correctable and noncor-
rectable folding defects in CFTR, we deleted F508 from the
CFTR N-terminal fragment 837X and examined its ability to
facilitate the formation of the maturely glycosylated form of
CFTR 837-1480 in the presence of Corr-4a. As reported
above, deletion of the F508 residue destabilizes CFTR 837X
in a manner that is noncorrectable by Corr-4a (Figures 3B
and 5B). Coexpression of CFTR 837XF508, and the wild-
type C-terminal fragment resulted in increased levels of the
B-form of CFTR 837-1480, but no observable mature CFTR
product (Rosser et al., 2008; Figure 5D). Interestingly, the
addition of Corr-4a did not result in the appearance of the
mature, highly glycosylated form of CFTR 837-1480 when
coexpressed with CFTR 837XF508. Yet, Corr-4a treatment
still promotes the accumulation of CFTR 837-1480 even when it
is coexpressed with the N-terminal CFTR 837XF508 fragment.
Thus, factors in addition to stabilization of the C-terminal
domains of CFTR by Corr-4a appear to be involved in the
correction of F508 folding defects.
Next, we probed the ability of Corr-4a to enhance the
proper association of CFTR 837X V232D with CFTR 837-
1480. We observed that, when compared with the wild-type
837X fragment, the steady-state levels of CFTR 837X V232D
were decreased (Figure 5B). Yet, the levels of CFTR 837X
V232D were increased upon Corr-4a treatment. Further-
more, pulse-chase analysis demonstrated that Corr-4a stabi-
lizes CFTR 837X V232D (Figure 5C). In addition, the levels of
the C-terminal fragment, 837-1480, were increased when
coexpressed with the CFTR 837X V232D mutant fragment
(Figure 5D). However, coexpression of this mutant N-termi-
nal fragment with the wild-type C-terminal fragment did
not produce a mature product. Yet, when Corr-4a was
present, a large subpopulation of the 837X V232D and 837-
Figure 5. Corr-4a stabilizes the MSDs of
CFTR. (A) Domain schematic of CFTR halves:
CFTR 837X and CFTR 837-1480. When CFTR
837-1480 is expressed alone it accumulates as an
immaturely glycosylated species. Coexpression
of the two halves of wild-type CFTR promotes
the formation of a maturely glycosylated form
of CFTR 837-1480. (B) HEK293 cells transfected
individually with CFTR 837X (1 g), CFTR
837XF508 (1 g), CFTR 837X V232D (1 g), or
CFTR 837-1480 (1 g) were cultured for 18 h
before addition of Corr-4a or DMSO. Cells were
incubated with chemicals for 24 h. Steady-state
levels were then determined by Western blot
analysis using CFTR N-terminal or NBD2-spe-
cific antibodies. Loading consistency was indi-
cated with tubulin blots. The B-band levels for
each reaction were quantified by densitometry
and were normalized to the DMSO-treated con-
trol. (C) Corr-4a increases the stability of CFTR
837X V232D and CFTR 837-1480. HEK293 cells
transfected with either CFTR 837X V232D or
CFTR 837-1480 were preincubated with Corr-4a
or DMSO for 2 h, labeled with [35S]methionine,
and chased for the indicated amounts of time in
the continuous presence of chemical treatment.
Soluble cell lysates were normalized to contain
the same total amount of protein, and CFTR
was immunoprecipitated with a CFTR N-termi-
nal– or NBD2–specific antibody. The reactions
were visualized by SDS-PAGE analysis and au-
toradiography. Results were quantified by den-
sitometry and normalized to the amount of B-
band at t  0 for each CFTR construct and
chemical treatment. (D) HEK293 cells were
transfected with either CFTR 837-1480, CFTR
837X and CFTR 837-1480, CFTR 837XF508 and
CFTR 837-1480, or CFTR 837X V232D and CFTR
837-1480. Transfected cells were cultured and
incubated with chemicals as in B. Steady-state levels of CFTR 837-1480 were determined by Western blot using a NBD2 specific antibody,
whereas the levels of the N-terminal fragments were analyzed with a CFTR N-terminal antibody. Maturely glycosylated CFTR 837-1480 is
designated as C-band, whereas the immaturely glycosylated form is indicated as B-band. Tubulin is used as a loading control. Results shown
are representative of one experiment; however, the reported observations were repeatedly observed.
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1480 fragments could assemble to form a mature CFTR
product (Figure 5D). Thus, Corr-4a is able to correct defects
in MSD1 folding to the degree that it facilitates the proper
assembly of CFTR 837X V232D and CFTR 837-1480. Collec-
tively, it appears that Corr-4a can impact the stability of
CFTR fragments that contain MSD2 and mutant forms of
MDS1, which in turn helps to augment CFTR folding.
Enhancement of CFTRF508 Folding by Combined Use of
Corr-4a and Suppressor Mutations
Corr-4a is capable of stabilizing fragments of CFTR that
contain MSD1 as well as MSD2 and may consequently in-
crease the folding efficiency of CFTR and different CFTR
mutants (Figure 5). Yet, it appears that multiple folding
defects limit the rescue of CFTRF508, whereas a less com-
plex mutant, such as CFTR V232D, is readily rescued. The
loss of contact between NBD1 and surfaces in CL4 of MSD2
was recently implicated as a critical step in CFTRF508
misfolding (Mornon et al., 2008; Serohijos et al., 2008). Thus,
we sought to restore such contacts and determine if this
augmented the potency of Corr-4a action in promoting the
folding of full-length CFTRF508.
Molecular modeling suggests that conversion of V510 to
an Asp in NBD1 generates contacts with R1070 in CL4,
thereby reinforcing the NBD1-MSD2 interface that is desta-
bilized by loss of F508 (Mornon et al., 2008). Indeed, intro-
duction of the V510D suppressor point mutation into
CFTRF508 partially restored folding of some CFTRF508
V510D (Wang et al., 2007), but the majority of CFTRF508
V510D accumulated in its B-form (Figure 6A), and the level
of repair remained below the observed levels of folded
wild-type CFTR (compare to CFTR panel in Figure 3B).
Corr-4a was able to enhance the accumulation of the folded
C-form of CFTRF508 V510D (Figure 6A). Pulse-chase anal-
ysis indicated that Corr-4a stabilizes the B-form and en-
hances the folding efficiency of CFTRF508 V510D (Figure
6B). These data are impressive since Corr-4a-dependent en-
hancement of CFTRF508 folding efficiency is weak and
difficult to detect in pulse-chase experiments (Figure 2B).
Overall, the V510D suppressor mutation and Corr-4a appear
to act in an additive manner to restore the folding of
CFTRF508 toward wild-type levels.
Corr-4a appears to be able to stabilize CFTRF508 after
MSD2 synthesis, yet this compound can only stabilize the
B-form of CFTR 1172XF508 and does not enhance folding
of this CFTR fragment to a level that can be detected in
biochemical assays (Figure 3). We reasoned that this result
reflects a role for the proposed NBD2-MSD1 interactions
(Mornon et al., 2008; Serohijos et al., 2008) in stabilizing the
conformation of CFTR when the F508 residue is missing. To
test this model, we asked if the V510D suppressor muta-
tion permits Corr-4a to correct the misfolding of CFTR
1172XF508. Suppression of CFTR 1172XF508 misfolding
upon introduction of the V510D mutation was similar to the
folding correction observed with CFTRF508 V510D (Figure
6A). Corr-4a was now able to promote the proper folding of
a small pool of CFTR 1172XF508 V510D and enhance the
accumulation of its maturely glycosylated C-form. How-
ever, again the level of correction was low and an increase in
the folding efficiency of CFTR 1172XF508 V510D was not
detected in pulse-chase experiments (Figure 6B).
These data suggest that proper folding of CFTR becomes
dependent upon NBD2 when the F508 residue is deleted,
and the global conformation of CFTR is destabilized by the
loss of interactions between NBD1 and CL4 of MSD2. Our
data indicates that Corr-4a modulates the conformation of
CFTR MSDs, which in turn promotes proper folding of
CFTR by permitting the formation of stable contacts be-
tween its N- and C-terminal regions.
DISCUSSION
Decreasing the endogenous pools of the E3 ubiquitin ligases
RMA1 or CHIP permits a subpopulation of CFTRF508 to
Figure 6. Enhancement of CFTRF508 folding by combined use of
Corr-4a and suppressor mutations. (A) HEK293 cells were trans-
fected with 1 g of either CFTRF508, CFTRF508 V510D, CFTR
1172XF508, or CFTR 1172XF508 V510D. Chemicals Corr-4a or
DMSO were added to the cells 18 h after transfection, and the cells
were incubated with the chemicals for 24 h. Steady-state levels were
then determined by Western blot analysis. Tubulin serves as a
loading control. The B- and C-band levels for each reaction were
quantified by densitometry and were normalized to the DMSO-
treated control. (B) HEK293 cells transfected with the indicated
CFTR plasmids were incubated with Corr-4a or DMSO for 2 h. Next,
the cells were pulse-labeled with [35S]methionine and chased for the
indicated time periods in the presence of chemical treatment. Solu-
ble cell lysates were normalized to total amount of protein, immu-
noprecipitated with a CFTR N-terminal antibody, and visualized by
SDS-PAGE analysis and autoradiography. Results were quantified
by densitometry and normalized to the amount of B-band at t  0
min for each condition. Similar trends were observed upon repeti-
tion of the experiments shown in A and B.
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fold, escape the ER, and accumulate as a maturely glycosy-
lated species. In the absence of these ERQC factors, Corr-4a
is dramatically more effective at rescuing folding defects in
CFTRF508. The increases in folding efficiency observed via
these manipulations are not complete, so it is clear that
folding kinetics as well as the activity of ERQC machinery
control the fate of nascent CFTR and CFTRF508. Previ-
ous approaches to inactivate ERQC factors and rescue
CFTRF508 misfolding relied on overexpression of domi-
nant negative E2 proteins (Younger et al., 2004). Such an
approach stabilized CFTRF508 in a foldable state, but did
not permit its folding to a form that could escape the ER
(Younger et al., 2004). The observation that knockdown of
endogenous RMA1 or CHIP can rescue folding defects of
CFTRF508 is consistent with observations that knockdown
of Hsp70/Hsp90 cochaperones permits proper folding of
CFTRF508 (Wang et al., 2006a). Cells often have a difficult
time compensating for the loss of cochaperones because they
have a broad array of general and essential cellular housekeep-
ing functions (Cyr et al., 2002). However, cells often tolerate the
loss of ER quality control factors well (Wilhovsky et al., 2000;
Dai et al., 2003). Thus, the development of approaches to inac-
tivate specific E3 ubiquitin ligases (Burger and Seth, 2004; Lee
et al., 2008) have the potential to permit foldable pools of
CFTRF508 or other disease-causing mutants to accumulate
and may serve as a means to treat CF.
Deletion of F508 from CFTR causes multiple folding de-
fects that occur during and after completion of biosynthesis
(Chen et al., 2004; Du et al., 2005; Thibodeau et al., 2005;
Mornon et al., 2008; Rosser et al., 2008; Serohijos et al., 2008;
Du and Lukacs, 2009). Our studies on the mechanism for
Corr-4a action indicate that deletion of F508 causes both
correctable and noncorrectable defects in CFTR folding. For-
mation of a stable folding intermediate by MSD1, NBD1, and
the R-domain requires F508 and assembly defects caused by
loss of F508 in CFTR 837X appear to be recognized by the
RMA1 E3 ligase (Rosser et al., 2008). Interestingly, Corr-4a is
not able to correct the folding defects of CFTR 837XF508.
Thus, studies with this CFTR fragment suggests that Corr-4a
acts after large pools of nascent CFTRF508 have been tar-
geted for degradation by the RMA1 ligase. This observation
explains why Corr-4a is ineffective at rescuing larger popu-
lations of misfolded CFTRF508. However, wild-type CFTR
becomes resistant to RMA1 action once MSD2 is present
(Younger et al., 2006), and Corr-4a is now able to increase
the folding efficiency of CFTR 1172X and stabilize CFTR
1172XF508. The E3 ligase CHIP does not appear to monitor
the folding status of CFTR until the last subdomain, NBD2,
is synthesized (Younger et al., 2006). Thus, the population of
CFTR that is able to make it past the RMA1 E3 ligase can be
acted upon by Corr-4a, and its folding status can be moni-
tored by the CHIP E3 ligase.
CFTR 1172X can fold and escape the ER (Cui et al., 2007),
but we were unable to biochemically detect folding of chem-
ical-treated CFTR 1172XF508. Thus, although NBD2 is not
required for maturation of CFTR 1172X, the contribution of
NBD2 to the folding of F508-containing mutants is re-
quired for maximal Corr-4a action. It appears that the pre-
dicted contacts between side chains in NBD2 and MSD1
(Mornon et al., 2008; Serohijos et al., 2008) are required for
the maximal activity of Corr-4a in correction of folding
defects caused by loss of the F508 residue. The need for such
contacts can be overcome when contacts between NBD1 and
MSD2, which are disrupted when F508 is deleted, are re-
stored upon introduction of suppressor mutations in NBD1.
Thus, interactions between solvent-exposed residues on
NBD2 and MSD1, as well as NBD1 and MSD2, participate
in CFTR and CFTRF508 assembly (Mornon et al., 2008;
Serohijos et al., 2008).
Our data, and those of others (Wang et al., 2006b; Loo et al.,
2008), suggest that the mechanism of Corr-4a action involves
the alteration of the conformation of CFTR’s MSDs. The
conformation of MSD1 is altered after deletion of F508 (Cui
et al., 2007; Rosser et al., 2008). As well, MSD2 is an unstable
domain in wild-type CFTR that is chaperoned by calnexin
(Rosser et al., 2008) and becomes misfolded and more sen-
sitive to proteolytic digestion in CFTRF508 (Du and
Lukacs, 2009). Corr-4a promotes the accumulation of the
MSD2 containing fragment CFTR 837-1480 and enhances
assembly of CFTR 837-1480 with CFTR 837X. Corr-4a is also
able to act on CFTR 837X V232D, and enhance its accumu-
lation. In full-length CFTR, Corr-4a induced correction is not
observed until after synthesis of MSD2. Thus, Corr-4a ap-
pears able to alter the conformation of MSDs of CFTR to
enhance formation of proper interdomain contacts between
MSD2 and other CFTR subdomains. Yet, Corr-4a is signifi-
cantly more effective at promoting the folding of CFTRF508
V510D than CFTRF508. The V510D mutant is designed to
facilitate interactions between NBD1 and MSD2 that are
defective when F508 is deleted (Mornon et al., 2008). Thus, it
appears that restoration of these contacts combined with
stabilization of MSD2 by Corr-4a is important for correction
of CFTRF508 misfolding.
Interestingly, the affect of Corr-4a on the accumulation
of CF disease-causing mutations contained within MSDs of
CFTR was highly variable. Corr-4a–dependent rescue of
MSD biogenic mutants G91R and M1137R was no greater
than that observed with corrector-treated CFTRF508. Fur-
thermore, the folding defect of the MSD1 mutant G85E
appeared to be largely noncorrectable by Corr-4a. Surpris-
ingly, there was a dramatic enhancement of CFTR V232D
folding by Corr-4a. In addition, Corr-4a was able to enhance
the accumulation of CFTR 837X V232D and to increase levels
of the mature, highly glycosylated form of CFTR 837-1480
with CFTR 837X V232D. The V232D mutant presents a mild
form of CF (Alonso et al., 2007); however, the molecular basis
for CF associated with this mutation has not been well-
defined. The V232D mutation is proposed to form an aber-
rant hydrogen bond in MSD1 (Therien et al., 2001; Choi et al.,
2004) that may hinder formation of interdomain contacts
between MSD1 and MSD2 that are proposed to occur in the
folded CFTR channel (Dawson and Locher, 2006; Serohijos et
al., 2008). Corr-4a is a hydrophobic molecule that may act by
forming contacts within the hydrophobic transmembrane
helices of CFTR or it may influence the lipid environment
that surrounds CFTR. Nevertheless, Corr-4a can act on N-
and C-terminal regions of CFTR and its mechanism of action
is not specific to correction of folding defects caused by the
F508 deletion.
Complex folding defects that involve multiple domains
caused by deletion of F508 have thus far been difficult to
correct with small molecules. Yet, rare mutations, such as
V232D, which cause more specific folding defects (Therien et
al., 2001; Choi et al., 2004) are easier to correct. It therefore
seems prudent to define the mechanism for misfolding of
additional rare CF-causing mutations and to screen for
compounds that correct the folding defects caused by
mutations other than deletion of F508. Rare mutations
impact a small population of CF patients, but helping at
least some of this patient population appears to be on the
immediate horizon.
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